Atara Biotherapeutics, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before May 22, 2026 to Discuss Your Rights – ATRA

Levi & Korsinsky announces a class action securities lawsuit against Atara Biotherapeutics for alleged fraud between May 20, 2024 and January 9, 2026. The complaint alleges the company made false statements about manufacturing issues and deficiencies in the ALLELE study that made FDA approval of tabelecleucel unlikely, while overstating regulatory prospects. Investors who suffered losses during this period can request lead plaintiff status by May 22, 2026.